NASDAQ:KMDA

Kamada Competitors

$6.14
-0.03 (-0.49 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.08
Now: $6.14
$6.21
50-Day Range
$6.02
MA: $6.25
$6.75
52-Week Range
$5.78
Now: $6.14
$13.33
Volume70,214 shs
Average Volume212,729 shs
Market Capitalization$273.35 million
P/E Ratio12.79
Dividend YieldN/A
Beta1.1

Competitors

Kamada (NASDAQ:KMDA) Vs. MRSN, CNST, ZGNX, TRIL, GTHX, and SNDX

Should you be buying KMDA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kamada, including Mersana Therapeutics (MRSN), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Trillium Therapeutics (TRIL), G1 Therapeutics (GTHX), and Syndax Pharmaceuticals (SNDX).

Mersana Therapeutics (NASDAQ:MRSN) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Mersana Therapeutics and Kamada, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mersana Therapeutics02502.71
Kamada00203.00

Mersana Therapeutics presently has a consensus target price of $26.1667, indicating a potential upside of 65.51%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Mersana Therapeutics.

Profitability

This table compares Mersana Therapeutics and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mersana Therapeutics-8,772.91%-45.16%-37.53%
Kamada15.60%12.89%10.66%

Risk and Volatility

Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

14.3% of Kamada shares are held by institutional investors. 5.3% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Mersana Therapeutics and Kamada's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mersana Therapeutics$42.12 million25.92$-28,210,000.00($0.65)-24.32
Kamada$127.19 million2.15$22.25 million$0.5511.16

Kamada has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Mersana Therapeutics on 10 of the 14 factors compared between the two stocks.

Constellation Pharmaceuticals (NASDAQ:CNST) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Constellation Pharmaceuticals and Kamada, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Constellation Pharmaceuticals02502.71
Kamada00203.00

Constellation Pharmaceuticals presently has a consensus target price of $45.2857, indicating a potential upside of 101.27%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Constellation Pharmaceuticals' higher probable upside, analysts clearly believe Constellation Pharmaceuticals is more favorable than Kamada.

Profitability

This table compares Constellation Pharmaceuticals and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Constellation PharmaceuticalsN/A-28.88%-24.98%
Kamada15.60%12.89%10.66%

Risk and Volatility

Constellation Pharmaceuticals has a beta of 2.8, indicating that its share price is 180% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

14.3% of Kamada shares are held by institutional investors. 10.6% of Constellation Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Kamada's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40
Kamada$127.19 million2.15$22.25 million$0.5511.16

Kamada has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Constellation Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Zogenix and Kamada, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zogenix01502.83
Kamada00203.00

Zogenix presently has a consensus target price of $58.25, indicating a potential upside of 202.28%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Zogenix's higher probable upside, analysts clearly believe Zogenix is more favorable than Kamada.

Profitability

This table compares Zogenix and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zogenix-8,758.48%-53.91%-36.49%
Kamada15.60%12.89%10.66%

Risk and Volatility

Zogenix has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

96.6% of Zogenix shares are held by institutional investors. Comparatively, 14.3% of Kamada shares are held by institutional investors. 3.5% of Zogenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Zogenix and Kamada's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zogenix$3.65 million294.26$-419,500,000.00($3.90)-4.94
Kamada$127.19 million2.15$22.25 million$0.5511.16

Kamada has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Zogenix on 8 of the 14 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Trillium Therapeutics and Kamada's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$120,000.008,945.66$-41,620,000.00($1.38)-7.55
Kamada$127.19 million2.15$22.25 million$0.5511.16

Kamada has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.5% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Trillium Therapeutics and Kamada, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics01502.83
Kamada00203.00

Trillium Therapeutics presently has a consensus target price of $22.00, indicating a potential upside of 111.13%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Trillium Therapeutics' higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Kamada.

Volatility and Risk

Trillium Therapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares Trillium Therapeutics and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/A-70.00%-28.84%
Kamada15.60%12.89%10.66%

Summary

Kamada beats Trillium Therapeutics on 8 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares G1 Therapeutics and Kamada's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-7.82
Kamada$127.19 million2.15$22.25 million$0.5511.16

Kamada has higher revenue and earnings than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for G1 Therapeutics and Kamada, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Kamada00203.00

G1 Therapeutics presently has a consensus target price of $49.1667, indicating a potential upside of 92.28%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given G1 Therapeutics' higher probable upside, equities analysts plainly believe G1 Therapeutics is more favorable than Kamada.

Volatility and Risk

G1 Therapeutics has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares G1 Therapeutics and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Kamada15.60%12.89%10.66%

Summary

Kamada beats G1 Therapeutics on 7 of the 12 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Syndax Pharmaceuticals and Kamada's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
Kamada$127.19 million2.15$22.25 million$0.5511.16

Kamada has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Syndax Pharmaceuticals and Kamada, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
Kamada00203.00

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, indicating a potential upside of 28.82%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Syndax Pharmaceuticals.

Volatility and Risk

Syndax Pharmaceuticals has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares Syndax Pharmaceuticals and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Kamada15.60%12.89%10.66%

Summary

Kamada beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Kamada Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00News Coverage
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27News Coverage
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90News Coverage
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87-0.4%$881.43 millionN/A-10.64Analyst Report
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.06-1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00News Coverage
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.